nodes	percent_of_prediction	percent_of_DWPC	metapath
Olanzapine—HRH1—atherosclerosis	0.374	0.812	CbGaD
Olanzapine—ALB—atherosclerosis	0.0864	0.188	CbGaD
Olanzapine—ALB—Rosuvastatin—atherosclerosis	0.0342	0.0976	CbGbCtD
Olanzapine—CYP2C19—Rosuvastatin—atherosclerosis	0.0222	0.0633	CbGbCtD
Olanzapine—CYP2C19—Simvastatin—atherosclerosis	0.0206	0.0588	CbGbCtD
Olanzapine—CYP2C19—Lovastatin—atherosclerosis	0.0202	0.0576	CbGbCtD
Olanzapine—CYP2D6—Niacin—atherosclerosis	0.0198	0.0566	CbGbCtD
Olanzapine—CYP2C9—Rosuvastatin—atherosclerosis	0.0184	0.0526	CbGbCtD
Olanzapine—ABCB1—Ezetimibe—atherosclerosis	0.0179	0.0511	CbGbCtD
Olanzapine—CYP2C9—Simvastatin—atherosclerosis	0.0171	0.0489	CbGbCtD
Olanzapine—CYP2C9—Pravastatin—atherosclerosis	0.0168	0.0479	CbGbCtD
Olanzapine—CYP2C9—Lovastatin—atherosclerosis	0.0168	0.0479	CbGbCtD
Olanzapine—ABCB1—Simvastatin—atherosclerosis	0.0166	0.0475	CbGbCtD
Olanzapine—ABCB1—Pravastatin—atherosclerosis	0.0163	0.0464	CbGbCtD
Olanzapine—ABCB1—Lovastatin—atherosclerosis	0.0163	0.0464	CbGbCtD
Olanzapine—CYP2D6—Simvastatin—atherosclerosis	0.0157	0.0447	CbGbCtD
Olanzapine—CYP2D6—Lovastatin—atherosclerosis	0.0153	0.0438	CbGbCtD
Olanzapine—CYP2D6—Pravastatin—atherosclerosis	0.0153	0.0438	CbGbCtD
Olanzapine—CYP3A4—Ezetimibe—atherosclerosis	0.0107	0.0306	CbGbCtD
Olanzapine—CYP3A4—Rosuvastatin—atherosclerosis	0.0107	0.0306	CbGbCtD
Olanzapine—CYP3A4—Simvastatin—atherosclerosis	0.00996	0.0284	CbGbCtD
Olanzapine—CYP3A4—Pravastatin—atherosclerosis	0.00975	0.0278	CbGbCtD
Olanzapine—CYP3A4—Lovastatin—atherosclerosis	0.00975	0.0278	CbGbCtD
Olanzapine—Emedastine—HRH1—atherosclerosis	0.00466	0.777	CrCbGaD
Olanzapine—HTR2A—arteriole—atherosclerosis	0.00246	0.0816	CbGeAlD
Olanzapine—HTR7—vein—atherosclerosis	0.00235	0.078	CbGeAlD
Olanzapine—HTR2A—vein—atherosclerosis	0.00147	0.0487	CbGeAlD
Olanzapine—HTR1B—artery—atherosclerosis	0.00124	0.0412	CbGeAlD
Olanzapine—HTR1D—artery—atherosclerosis	0.0012	0.0399	CbGeAlD
Olanzapine—HTR2A—hindlimb—atherosclerosis	0.000974	0.0323	CbGeAlD
Olanzapine—HTR1B—blood vessel—atherosclerosis	0.000967	0.0321	CbGeAlD
Olanzapine—HTR7—artery—atherosclerosis	0.000957	0.0318	CbGeAlD
Olanzapine—HTR1D—blood vessel—atherosclerosis	0.000936	0.0311	CbGeAlD
Olanzapine—HTR2A—appendage—atherosclerosis	0.000836	0.0277	CbGeAlD
Olanzapine—HTR7—endothelium—atherosclerosis	0.000809	0.0269	CbGeAlD
Olanzapine—HTR7—blood vessel—atherosclerosis	0.000746	0.0248	CbGeAlD
Olanzapine—HRH2—cardiovascular system—atherosclerosis	0.000654	0.0217	CbGeAlD
Olanzapine—FMO3—adipose tissue—atherosclerosis	0.000648	0.0215	CbGeAlD
Olanzapine—H1F0—connective tissue—atherosclerosis	0.00062	0.0206	CbGeAlD
Olanzapine—HTR2A—artery—atherosclerosis	0.000597	0.0198	CbGeAlD
Olanzapine—H1F0—cardiovascular system—atherosclerosis	0.000539	0.0179	CbGeAlD
Olanzapine—HTR2A—endothelium—atherosclerosis	0.000504	0.0167	CbGeAlD
Olanzapine—HTR1D—connective tissue—atherosclerosis	0.00048	0.0159	CbGeAlD
Olanzapine—H1F0—adipose tissue—atherosclerosis	0.000475	0.0158	CbGeAlD
Olanzapine—HTR2A—blood vessel—atherosclerosis	0.000465	0.0154	CbGeAlD
Olanzapine—FMO3—liver—atherosclerosis	0.000455	0.0151	CbGeAlD
Olanzapine—HTR1B—cardiovascular system—atherosclerosis	0.000431	0.0143	CbGeAlD
Olanzapine—CHRM2—cardiovascular system—atherosclerosis	0.000429	0.0142	CbGeAlD
Olanzapine—Amoxapine—HRH1—atherosclerosis	0.000418	0.0698	CrCbGaD
Olanzapine—HTR1D—cardiovascular system—atherosclerosis	0.000418	0.0139	CbGeAlD
Olanzapine—HRH2—liver—atherosclerosis	0.000405	0.0134	CbGeAlD
Olanzapine—CHRM1—cardiovascular system—atherosclerosis	0.000391	0.013	CbGeAlD
Olanzapine—HTR2B—cardiovascular system—atherosclerosis	0.000389	0.0129	CbGeAlD
Olanzapine—HTR7—connective tissue—atherosclerosis	0.000382	0.0127	CbGeAlD
Olanzapine—HTR1A—cardiovascular system—atherosclerosis	0.000348	0.0116	CbGeAlD
Olanzapine—HTR2B—adipose tissue—atherosclerosis	0.000343	0.0114	CbGeAlD
Olanzapine—H1F0—liver—atherosclerosis	0.000333	0.0111	CbGeAlD
Olanzapine—HTR7—cardiovascular system—atherosclerosis	0.000333	0.011	CbGeAlD
Olanzapine—Loxapine—HRH1—atherosclerosis	0.000327	0.0545	CrCbGaD
Olanzapine—ADRA1A—cardiovascular system—atherosclerosis	0.000321	0.0107	CbGeAlD
Olanzapine—Quetiapine—HRH1—atherosclerosis	0.000319	0.0532	CrCbGaD
Olanzapine—CHRM3—adipose tissue—atherosclerosis	0.000308	0.0102	CbGeAlD
Olanzapine—ABCB1—blood vessel—atherosclerosis	0.000305	0.0101	CbGeAlD
Olanzapine—HRH1—connective tissue—atherosclerosis	0.000286	0.00948	CbGeAlD
Olanzapine—ORM1—liver—atherosclerosis	0.000285	0.00945	CbGeAlD
Olanzapine—ADRA1A—adipose tissue—atherosclerosis	0.000283	0.0094	CbGeAlD
Olanzapine—ADRA2A—connective tissue—atherosclerosis	0.00028	0.00931	CbGeAlD
Olanzapine—Clozapine—HRH1—atherosclerosis	0.000274	0.0458	CrCbGaD
Olanzapine—ADRA2C—adipose tissue—atherosclerosis	0.00027	0.00895	CbGeAlD
Olanzapine—CYP2C9—cardiovascular system—atherosclerosis	0.000252	0.00836	CbGeAlD
Olanzapine—ALB—liver—atherosclerosis	0.00025	0.00829	CbGeAlD
Olanzapine—HTR2A—connective tissue—atherosclerosis	0.000238	0.00792	CbGeAlD
Olanzapine—HRH1—adipose tissue—atherosclerosis	0.000219	0.00727	CbGeAlD
Olanzapine—ADRA2A—adipose tissue—atherosclerosis	0.000215	0.00714	CbGeAlD
Olanzapine—HTR2A—cardiovascular system—atherosclerosis	0.000207	0.00689	CbGeAlD
Olanzapine—HTR7—liver—atherosclerosis	0.000206	0.00683	CbGeAlD
Olanzapine—CYP2C19—liver—atherosclerosis	0.000201	0.00667	CbGeAlD
Olanzapine—ADRA1A—liver—atherosclerosis	0.000198	0.00659	CbGeAlD
Olanzapine—ADRA2C—liver—atherosclerosis	0.000189	0.00628	CbGeAlD
Olanzapine—CYP1A2—liver—atherosclerosis	0.000164	0.00545	CbGeAlD
Olanzapine—CYP2C9—liver—atherosclerosis	0.000156	0.00517	CbGeAlD
Olanzapine—ABCB1—cardiovascular system—atherosclerosis	0.000136	0.00451	CbGeAlD
Olanzapine—HTR2A—liver—atherosclerosis	0.000128	0.00426	CbGeAlD
Olanzapine—ABCB1—adipose tissue—atherosclerosis	0.00012	0.00398	CbGeAlD
Olanzapine—CYP3A4—liver—atherosclerosis	0.000119	0.00394	CbGeAlD
Olanzapine—CYP2D6—liver—atherosclerosis	0.000117	0.00388	CbGeAlD
Olanzapine—ABCB1—liver—atherosclerosis	8.41e-05	0.00279	CbGeAlD
Olanzapine—CYP2D6—Metabolism—APOA1—atherosclerosis	2.13e-06	1.39e-05	CbGpPWpGaD
Olanzapine—CHRM5—Signaling Pathways—TGFB1—atherosclerosis	2.13e-06	1.39e-05	CbGpPWpGaD
Olanzapine—CYP1A2—Metabolism—GPX1—atherosclerosis	2.12e-06	1.39e-05	CbGpPWpGaD
Olanzapine—ADRA2B—Signaling by GPCR—AKT1—atherosclerosis	2.12e-06	1.39e-05	CbGpPWpGaD
Olanzapine—DRD5—Signaling Pathways—AKT1—atherosclerosis	2.12e-06	1.39e-05	CbGpPWpGaD
Olanzapine—ADRA1B—Signaling by GPCR—IL6—atherosclerosis	2.12e-06	1.38e-05	CbGpPWpGaD
Olanzapine—CYP2C9—Metabolism—CAV1—atherosclerosis	2.11e-06	1.38e-05	CbGpPWpGaD
Olanzapine—HTR1A—Signaling Pathways—MMP9—atherosclerosis	2.11e-06	1.38e-05	CbGpPWpGaD
Olanzapine—CYP2C19—Metabolism—PIK3CG—atherosclerosis	2.11e-06	1.38e-05	CbGpPWpGaD
Olanzapine—CYP2C9—Metabolism—APOA1—atherosclerosis	2.11e-06	1.38e-05	CbGpPWpGaD
Olanzapine—HTR2C—Signaling Pathways—MMP9—atherosclerosis	2.1e-06	1.37e-05	CbGpPWpGaD
Olanzapine—HTR1A—Signaling Pathways—NFKB1—atherosclerosis	2.09e-06	1.37e-05	CbGpPWpGaD
Olanzapine—DRD1—Signaling Pathways—MAPK3—atherosclerosis	2.09e-06	1.36e-05	CbGpPWpGaD
Olanzapine—HTR2C—Signaling Pathways—NFKB1—atherosclerosis	2.08e-06	1.36e-05	CbGpPWpGaD
Olanzapine—ADRA2A—Signaling Pathways—NOS3—atherosclerosis	2.07e-06	1.35e-05	CbGpPWpGaD
Olanzapine—CYP1A2—Metabolism—CD36—atherosclerosis	2.07e-06	1.35e-05	CbGpPWpGaD
Olanzapine—ABCB1—Metabolism—PIK3CG—atherosclerosis	2.06e-06	1.35e-05	CbGpPWpGaD
Olanzapine—DRD3—Signaling Pathways—MAPK3—atherosclerosis	2.06e-06	1.35e-05	CbGpPWpGaD
Olanzapine—HTR1A—Signaling Pathways—MAPK8—atherosclerosis	2.06e-06	1.34e-05	CbGpPWpGaD
Olanzapine—DRD2—Signaling Pathways—CXCL8—atherosclerosis	2.05e-06	1.34e-05	CbGpPWpGaD
Olanzapine—HTR1A—Signaling by GPCR—AKT1—atherosclerosis	2.05e-06	1.34e-05	CbGpPWpGaD
Olanzapine—ADRA2C—Signaling Pathways—MMP9—atherosclerosis	2.04e-06	1.34e-05	CbGpPWpGaD
Olanzapine—HTR2C—Signaling Pathways—MAPK8—atherosclerosis	2.04e-06	1.34e-05	CbGpPWpGaD
Olanzapine—CYP2C19—Metabolism—PPARG—atherosclerosis	2.04e-06	1.33e-05	CbGpPWpGaD
Olanzapine—HTR2C—Signaling by GPCR—AKT1—atherosclerosis	2.04e-06	1.33e-05	CbGpPWpGaD
Olanzapine—DRD1—Signaling Pathways—TGFB1—atherosclerosis	2.03e-06	1.32e-05	CbGpPWpGaD
Olanzapine—ADRA2C—Signaling Pathways—NFKB1—atherosclerosis	2.02e-06	1.32e-05	CbGpPWpGaD
Olanzapine—HTR2A—Signaling Pathways—CXCL8—atherosclerosis	2.02e-06	1.32e-05	CbGpPWpGaD
Olanzapine—HRH1—Signaling Pathways—CXCL8—atherosclerosis	2.01e-06	1.32e-05	CbGpPWpGaD
Olanzapine—ADRA1B—Signaling Pathways—MMP9—atherosclerosis	2.01e-06	1.32e-05	CbGpPWpGaD
Olanzapine—CHRM1—Signaling Pathways—CXCL8—atherosclerosis	2.01e-06	1.31e-05	CbGpPWpGaD
Olanzapine—CHRM3—Signaling Pathways—CXCL8—atherosclerosis	2e-06	1.31e-05	CbGpPWpGaD
Olanzapine—CYP2C19—Metabolism—INS—atherosclerosis	2e-06	1.31e-05	CbGpPWpGaD
Olanzapine—DRD3—Signaling Pathways—TGFB1—atherosclerosis	2e-06	1.31e-05	CbGpPWpGaD
Olanzapine—ADRA1B—Signaling Pathways—NFKB1—atherosclerosis	1.99e-06	1.3e-05	CbGpPWpGaD
Olanzapine—ABCB1—Metabolism—PPARG—atherosclerosis	1.99e-06	1.3e-05	CbGpPWpGaD
Olanzapine—ADRA2C—Signaling Pathways—MAPK8—atherosclerosis	1.99e-06	1.3e-05	CbGpPWpGaD
Olanzapine—ADRA2C—Signaling by GPCR—AKT1—atherosclerosis	1.98e-06	1.3e-05	CbGpPWpGaD
Olanzapine—CHRM2—Signaling Pathways—CXCL8—atherosclerosis	1.98e-06	1.3e-05	CbGpPWpGaD
Olanzapine—DRD2—GPCR downstream signaling—AKT1—atherosclerosis	1.98e-06	1.3e-05	CbGpPWpGaD
Olanzapine—ADRA1A—Signaling Pathways—CXCL8—atherosclerosis	1.98e-06	1.29e-05	CbGpPWpGaD
Olanzapine—ADRA2B—Signaling Pathways—VEGFA—atherosclerosis	1.97e-06	1.29e-05	CbGpPWpGaD
Olanzapine—CYP1A2—Metabolism—MTHFR—atherosclerosis	1.96e-06	1.28e-05	CbGpPWpGaD
Olanzapine—ADRA1B—Signaling Pathways—MAPK8—atherosclerosis	1.96e-06	1.28e-05	CbGpPWpGaD
Olanzapine—ALB—Metabolism—NOS3—atherosclerosis	1.95e-06	1.28e-05	CbGpPWpGaD
Olanzapine—ABCB1—Metabolism—INS—atherosclerosis	1.95e-06	1.28e-05	CbGpPWpGaD
Olanzapine—ADRA1B—Signaling by GPCR—AKT1—atherosclerosis	1.95e-06	1.28e-05	CbGpPWpGaD
Olanzapine—DRD2—Signaling by GPCR—IL6—atherosclerosis	1.95e-06	1.28e-05	CbGpPWpGaD
Olanzapine—HTR2A—GPCR downstream signaling—AKT1—atherosclerosis	1.95e-06	1.27e-05	CbGpPWpGaD
Olanzapine—ADRA2B—Signaling Pathways—STAT3—atherosclerosis	1.95e-06	1.27e-05	CbGpPWpGaD
Olanzapine—HRH1—GPCR downstream signaling—AKT1—atherosclerosis	1.95e-06	1.27e-05	CbGpPWpGaD
Olanzapine—CYP2D6—Metabolism—PIK3CG—atherosclerosis	1.94e-06	1.27e-05	CbGpPWpGaD
Olanzapine—CHRM1—GPCR downstream signaling—AKT1—atherosclerosis	1.94e-06	1.27e-05	CbGpPWpGaD
Olanzapine—CHRM3—GPCR downstream signaling—AKT1—atherosclerosis	1.93e-06	1.26e-05	CbGpPWpGaD
Olanzapine—CYP2C9—Metabolism—PIK3CG—atherosclerosis	1.93e-06	1.26e-05	CbGpPWpGaD
Olanzapine—CYP1A2—Metabolism—PPARA—atherosclerosis	1.92e-06	1.26e-05	CbGpPWpGaD
Olanzapine—HTR2A—Signaling by GPCR—IL6—atherosclerosis	1.92e-06	1.25e-05	CbGpPWpGaD
Olanzapine—HRH1—Signaling by GPCR—IL6—atherosclerosis	1.91e-06	1.25e-05	CbGpPWpGaD
Olanzapine—CHRM2—GPCR downstream signaling—AKT1—atherosclerosis	1.91e-06	1.25e-05	CbGpPWpGaD
Olanzapine—ADRA1A—GPCR downstream signaling—AKT1—atherosclerosis	1.91e-06	1.25e-05	CbGpPWpGaD
Olanzapine—CHRM1—Signaling by GPCR—IL6—atherosclerosis	1.91e-06	1.25e-05	CbGpPWpGaD
Olanzapine—CHRM3—Signaling by GPCR—IL6—atherosclerosis	1.9e-06	1.24e-05	CbGpPWpGaD
Olanzapine—HTR1A—Signaling Pathways—VEGFA—atherosclerosis	1.9e-06	1.24e-05	CbGpPWpGaD
Olanzapine—HTR2C—Signaling Pathways—VEGFA—atherosclerosis	1.89e-06	1.23e-05	CbGpPWpGaD
Olanzapine—CHRM2—Signaling by GPCR—IL6—atherosclerosis	1.88e-06	1.23e-05	CbGpPWpGaD
Olanzapine—ADRA1A—Signaling by GPCR—IL6—atherosclerosis	1.88e-06	1.23e-05	CbGpPWpGaD
Olanzapine—HTR1A—Signaling Pathways—STAT3—atherosclerosis	1.88e-06	1.23e-05	CbGpPWpGaD
Olanzapine—CYP2D6—Metabolism—PPARG—atherosclerosis	1.88e-06	1.23e-05	CbGpPWpGaD
Olanzapine—HTR2C—Signaling Pathways—STAT3—atherosclerosis	1.87e-06	1.22e-05	CbGpPWpGaD
Olanzapine—CYP1A2—Metabolism—AGT—atherosclerosis	1.86e-06	1.22e-05	CbGpPWpGaD
Olanzapine—ADRA2B—Signaling Pathways—MAPK3—atherosclerosis	1.86e-06	1.22e-05	CbGpPWpGaD
Olanzapine—CYP2C9—Metabolism—PPARG—atherosclerosis	1.86e-06	1.22e-05	CbGpPWpGaD
Olanzapine—DRD2—Signaling Pathways—MMP9—atherosclerosis	1.86e-06	1.21e-05	CbGpPWpGaD
Olanzapine—CYP2D6—Metabolism—INS—atherosclerosis	1.84e-06	1.2e-05	CbGpPWpGaD
Olanzapine—CYP3A4—Metabolism—HMOX1—atherosclerosis	1.84e-06	1.2e-05	CbGpPWpGaD
Olanzapine—ADRA2A—Signaling Pathways—CXCL8—atherosclerosis	1.84e-06	1.2e-05	CbGpPWpGaD
Olanzapine—ADRA2C—Signaling Pathways—VEGFA—atherosclerosis	1.84e-06	1.2e-05	CbGpPWpGaD
Olanzapine—DRD2—Signaling Pathways—NFKB1—atherosclerosis	1.84e-06	1.2e-05	CbGpPWpGaD
Olanzapine—CYP2C19—Metabolism—ALB—atherosclerosis	1.83e-06	1.2e-05	CbGpPWpGaD
Olanzapine—HTR2A—Signaling Pathways—MMP9—atherosclerosis	1.83e-06	1.19e-05	CbGpPWpGaD
Olanzapine—CYP1A2—Metabolism—APOE—atherosclerosis	1.82e-06	1.19e-05	CbGpPWpGaD
Olanzapine—CYP2C9—Metabolism—INS—atherosclerosis	1.82e-06	1.19e-05	CbGpPWpGaD
Olanzapine—HRH1—Signaling Pathways—MMP9—atherosclerosis	1.82e-06	1.19e-05	CbGpPWpGaD
Olanzapine—ADRA2C—Signaling Pathways—STAT3—atherosclerosis	1.82e-06	1.19e-05	CbGpPWpGaD
Olanzapine—CHRM1—Signaling Pathways—MMP9—atherosclerosis	1.82e-06	1.19e-05	CbGpPWpGaD
Olanzapine—CHRM3—Signaling Pathways—MMP9—atherosclerosis	1.81e-06	1.18e-05	CbGpPWpGaD
Olanzapine—CYP1A2—Metabolism—CAV1—atherosclerosis	1.81e-06	1.18e-05	CbGpPWpGaD
Olanzapine—ADRA1B—Signaling Pathways—VEGFA—atherosclerosis	1.81e-06	1.18e-05	CbGpPWpGaD
Olanzapine—HTR2A—Signaling Pathways—NFKB1—atherosclerosis	1.81e-06	1.18e-05	CbGpPWpGaD
Olanzapine—DRD2—Signaling Pathways—MAPK8—atherosclerosis	1.8e-06	1.18e-05	CbGpPWpGaD
Olanzapine—ADRA2B—Signaling Pathways—TGFB1—atherosclerosis	1.8e-06	1.18e-05	CbGpPWpGaD
Olanzapine—CYP1A2—Metabolism—APOA1—atherosclerosis	1.8e-06	1.18e-05	CbGpPWpGaD
Olanzapine—HRH1—Signaling Pathways—NFKB1—atherosclerosis	1.8e-06	1.18e-05	CbGpPWpGaD
Olanzapine—DRD2—Signaling by GPCR—AKT1—atherosclerosis	1.8e-06	1.18e-05	CbGpPWpGaD
Olanzapine—CHRM1—Signaling Pathways—NFKB1—atherosclerosis	1.8e-06	1.17e-05	CbGpPWpGaD
Olanzapine—HTR1A—Signaling Pathways—MAPK3—atherosclerosis	1.79e-06	1.17e-05	CbGpPWpGaD
Olanzapine—CHRM2—Signaling Pathways—MMP9—atherosclerosis	1.79e-06	1.17e-05	CbGpPWpGaD
Olanzapine—CHRM3—Signaling Pathways—NFKB1—atherosclerosis	1.79e-06	1.17e-05	CbGpPWpGaD
Olanzapine—ABCB1—Metabolism—ALB—atherosclerosis	1.79e-06	1.17e-05	CbGpPWpGaD
Olanzapine—ADRA1B—Signaling Pathways—STAT3—atherosclerosis	1.79e-06	1.17e-05	CbGpPWpGaD
Olanzapine—ADRA1A—Signaling Pathways—MMP9—atherosclerosis	1.79e-06	1.17e-05	CbGpPWpGaD
Olanzapine—ALB—Metabolism—PTGS2—atherosclerosis	1.79e-06	1.17e-05	CbGpPWpGaD
Olanzapine—HTR2C—Signaling Pathways—MAPK3—atherosclerosis	1.79e-06	1.17e-05	CbGpPWpGaD
Olanzapine—HTR2A—Signaling Pathways—MAPK8—atherosclerosis	1.78e-06	1.16e-05	CbGpPWpGaD
Olanzapine—ADRA2A—GPCR downstream signaling—AKT1—atherosclerosis	1.77e-06	1.16e-05	CbGpPWpGaD
Olanzapine—CHRM2—Signaling Pathways—NFKB1—atherosclerosis	1.77e-06	1.16e-05	CbGpPWpGaD
Olanzapine—HTR6—Signaling Pathways—IL6—atherosclerosis	1.77e-06	1.16e-05	CbGpPWpGaD
Olanzapine—HRH1—Signaling Pathways—MAPK8—atherosclerosis	1.77e-06	1.16e-05	CbGpPWpGaD
Olanzapine—HTR7—Signaling Pathways—IL6—atherosclerosis	1.77e-06	1.16e-05	CbGpPWpGaD
Olanzapine—HTR2A—Signaling by GPCR—AKT1—atherosclerosis	1.77e-06	1.16e-05	CbGpPWpGaD
Olanzapine—ADRA1A—Signaling Pathways—NFKB1—atherosclerosis	1.77e-06	1.16e-05	CbGpPWpGaD
Olanzapine—HRH1—Signaling by GPCR—AKT1—atherosclerosis	1.77e-06	1.16e-05	CbGpPWpGaD
Olanzapine—CHRM1—Signaling Pathways—MAPK8—atherosclerosis	1.77e-06	1.15e-05	CbGpPWpGaD
Olanzapine—CHRM1—Signaling by GPCR—AKT1—atherosclerosis	1.76e-06	1.15e-05	CbGpPWpGaD
Olanzapine—CHRM3—Signaling Pathways—MAPK8—atherosclerosis	1.76e-06	1.15e-05	CbGpPWpGaD
Olanzapine—HTR1D—Signaling Pathways—IL6—atherosclerosis	1.76e-06	1.15e-05	CbGpPWpGaD
Olanzapine—CYP3A4—Metabolism—APOB—atherosclerosis	1.76e-06	1.15e-05	CbGpPWpGaD
Olanzapine—CHRM3—Signaling by GPCR—AKT1—atherosclerosis	1.76e-06	1.15e-05	CbGpPWpGaD
Olanzapine—CYP2C19—Metabolism—NOS3—atherosclerosis	1.75e-06	1.15e-05	CbGpPWpGaD
Olanzapine—ADRA2A—Signaling by GPCR—IL6—atherosclerosis	1.75e-06	1.14e-05	CbGpPWpGaD
Olanzapine—CHRM2—Signaling Pathways—MAPK8—atherosclerosis	1.74e-06	1.14e-05	CbGpPWpGaD
Olanzapine—HTR1A—Signaling Pathways—TGFB1—atherosclerosis	1.74e-06	1.14e-05	CbGpPWpGaD
Olanzapine—CHRM2—Signaling by GPCR—AKT1—atherosclerosis	1.74e-06	1.14e-05	CbGpPWpGaD
Olanzapine—ADRA1A—Signaling Pathways—MAPK8—atherosclerosis	1.74e-06	1.14e-05	CbGpPWpGaD
Olanzapine—ADRA2C—Signaling Pathways—MAPK3—atherosclerosis	1.74e-06	1.14e-05	CbGpPWpGaD
Olanzapine—ADRA1A—Signaling by GPCR—AKT1—atherosclerosis	1.73e-06	1.13e-05	CbGpPWpGaD
Olanzapine—HTR2C—Signaling Pathways—TGFB1—atherosclerosis	1.73e-06	1.13e-05	CbGpPWpGaD
Olanzapine—HTR1B—Signaling Pathways—IL6—atherosclerosis	1.72e-06	1.13e-05	CbGpPWpGaD
Olanzapine—ABCB1—Metabolism—NOS3—atherosclerosis	1.71e-06	1.12e-05	CbGpPWpGaD
Olanzapine—CYP3A4—Metabolism—GSTM1—atherosclerosis	1.71e-06	1.12e-05	CbGpPWpGaD
Olanzapine—ADRA1B—Signaling Pathways—MAPK3—atherosclerosis	1.71e-06	1.12e-05	CbGpPWpGaD
Olanzapine—DRD4—Signaling Pathways—IL6—atherosclerosis	1.7e-06	1.11e-05	CbGpPWpGaD
Olanzapine—CYP2D6—Metabolism—ALB—atherosclerosis	1.69e-06	1.1e-05	CbGpPWpGaD
Olanzapine—ADRA2C—Signaling Pathways—TGFB1—atherosclerosis	1.69e-06	1.1e-05	CbGpPWpGaD
Olanzapine—CYP3A4—Metabolism—LPL—atherosclerosis	1.68e-06	1.1e-05	CbGpPWpGaD
Olanzapine—CHRM4—Signaling Pathways—IL6—atherosclerosis	1.67e-06	1.09e-05	CbGpPWpGaD
Olanzapine—CYP2C9—Metabolism—ALB—atherosclerosis	1.67e-06	1.09e-05	CbGpPWpGaD
Olanzapine—DRD2—Signaling Pathways—VEGFA—atherosclerosis	1.67e-06	1.09e-05	CbGpPWpGaD
Olanzapine—ADRA2A—Signaling Pathways—MMP9—atherosclerosis	1.66e-06	1.09e-05	CbGpPWpGaD
Olanzapine—ADRA1B—Signaling Pathways—TGFB1—atherosclerosis	1.66e-06	1.08e-05	CbGpPWpGaD
Olanzapine—DRD2—Signaling Pathways—STAT3—atherosclerosis	1.65e-06	1.08e-05	CbGpPWpGaD
Olanzapine—CYP1A2—Metabolism—PIK3CG—atherosclerosis	1.65e-06	1.08e-05	CbGpPWpGaD
Olanzapine—ADRA2A—Signaling Pathways—NFKB1—atherosclerosis	1.64e-06	1.07e-05	CbGpPWpGaD
Olanzapine—HTR2A—Signaling Pathways—VEGFA—atherosclerosis	1.64e-06	1.07e-05	CbGpPWpGaD
Olanzapine—CYP3A4—Metabolism—GPX1—atherosclerosis	1.64e-06	1.07e-05	CbGpPWpGaD
Olanzapine—HRH1—Signaling Pathways—VEGFA—atherosclerosis	1.64e-06	1.07e-05	CbGpPWpGaD
Olanzapine—HTR6—Signaling Pathways—AKT1—atherosclerosis	1.64e-06	1.07e-05	CbGpPWpGaD
Olanzapine—HTR7—Signaling Pathways—AKT1—atherosclerosis	1.63e-06	1.07e-05	CbGpPWpGaD
Olanzapine—CHRM1—Signaling Pathways—VEGFA—atherosclerosis	1.63e-06	1.07e-05	CbGpPWpGaD
Olanzapine—CHRM3—Signaling Pathways—VEGFA—atherosclerosis	1.63e-06	1.06e-05	CbGpPWpGaD
Olanzapine—HTR1D—Signaling Pathways—AKT1—atherosclerosis	1.62e-06	1.06e-05	CbGpPWpGaD
Olanzapine—HTR2A—Signaling Pathways—STAT3—atherosclerosis	1.62e-06	1.06e-05	CbGpPWpGaD
Olanzapine—HRH1—Signaling Pathways—STAT3—atherosclerosis	1.62e-06	1.06e-05	CbGpPWpGaD
Olanzapine—HTR2B—Signaling Pathways—IL6—atherosclerosis	1.62e-06	1.06e-05	CbGpPWpGaD
Olanzapine—ADRA2A—Signaling Pathways—MAPK8—atherosclerosis	1.62e-06	1.06e-05	CbGpPWpGaD
Olanzapine—CHRM1—Signaling Pathways—STAT3—atherosclerosis	1.61e-06	1.06e-05	CbGpPWpGaD
Olanzapine—CYP2D6—Metabolism—NOS3—atherosclerosis	1.61e-06	1.05e-05	CbGpPWpGaD
Olanzapine—ADRA2A—Signaling by GPCR—AKT1—atherosclerosis	1.61e-06	1.05e-05	CbGpPWpGaD
Olanzapine—CHRM2—Signaling Pathways—VEGFA—atherosclerosis	1.61e-06	1.05e-05	CbGpPWpGaD
Olanzapine—CHRM3—Signaling Pathways—STAT3—atherosclerosis	1.61e-06	1.05e-05	CbGpPWpGaD
Olanzapine—ADRA1A—Signaling Pathways—VEGFA—atherosclerosis	1.61e-06	1.05e-05	CbGpPWpGaD
Olanzapine—CYP2C19—Metabolism—PTGS2—atherosclerosis	1.6e-06	1.05e-05	CbGpPWpGaD
Olanzapine—CHRM5—Signaling Pathways—IL6—atherosclerosis	1.6e-06	1.05e-05	CbGpPWpGaD
Olanzapine—CYP2C9—Metabolism—NOS3—atherosclerosis	1.6e-06	1.05e-05	CbGpPWpGaD
Olanzapine—CYP3A4—Metabolism—CD36—atherosclerosis	1.6e-06	1.04e-05	CbGpPWpGaD
Olanzapine—CHRM2—Signaling Pathways—STAT3—atherosclerosis	1.59e-06	1.04e-05	CbGpPWpGaD
Olanzapine—HTR1B—Signaling Pathways—AKT1—atherosclerosis	1.59e-06	1.04e-05	CbGpPWpGaD
Olanzapine—ADRA1A—Signaling Pathways—STAT3—atherosclerosis	1.59e-06	1.04e-05	CbGpPWpGaD
Olanzapine—CYP1A2—Metabolism—PPARG—atherosclerosis	1.59e-06	1.04e-05	CbGpPWpGaD
Olanzapine—DRD2—Signaling Pathways—MAPK3—atherosclerosis	1.58e-06	1.03e-05	CbGpPWpGaD
Olanzapine—ABCB1—Metabolism—PTGS2—atherosclerosis	1.57e-06	1.02e-05	CbGpPWpGaD
Olanzapine—DRD4—Signaling Pathways—AKT1—atherosclerosis	1.56e-06	1.02e-05	CbGpPWpGaD
Olanzapine—CYP1A2—Metabolism—INS—atherosclerosis	1.56e-06	1.02e-05	CbGpPWpGaD
Olanzapine—HTR2A—Signaling Pathways—MAPK3—atherosclerosis	1.55e-06	1.01e-05	CbGpPWpGaD
Olanzapine—HRH1—Signaling Pathways—MAPK3—atherosclerosis	1.55e-06	1.01e-05	CbGpPWpGaD
Olanzapine—CHRM4—Signaling Pathways—AKT1—atherosclerosis	1.54e-06	1.01e-05	CbGpPWpGaD
Olanzapine—CHRM1—Signaling Pathways—MAPK3—atherosclerosis	1.54e-06	1.01e-05	CbGpPWpGaD
Olanzapine—CHRM3—Signaling Pathways—MAPK3—atherosclerosis	1.54e-06	1.01e-05	CbGpPWpGaD
Olanzapine—DRD2—Signaling Pathways—TGFB1—atherosclerosis	1.53e-06	1e-05	CbGpPWpGaD
Olanzapine—DRD1—Signaling Pathways—IL6—atherosclerosis	1.53e-06	9.98e-06	CbGpPWpGaD
Olanzapine—CHRM2—Signaling Pathways—MAPK3—atherosclerosis	1.52e-06	9.95e-06	CbGpPWpGaD
Olanzapine—ADRA1A—Signaling Pathways—MAPK3—atherosclerosis	1.52e-06	9.93e-06	CbGpPWpGaD
Olanzapine—CYP3A4—Metabolism—MTHFR—atherosclerosis	1.51e-06	9.89e-06	CbGpPWpGaD
Olanzapine—DRD3—Signaling Pathways—IL6—atherosclerosis	1.51e-06	9.84e-06	CbGpPWpGaD
Olanzapine—HTR2A—Signaling Pathways—TGFB1—atherosclerosis	1.5e-06	9.84e-06	CbGpPWpGaD
Olanzapine—HRH1—Signaling Pathways—TGFB1—atherosclerosis	1.5e-06	9.81e-06	CbGpPWpGaD
Olanzapine—CHRM1—Signaling Pathways—TGFB1—atherosclerosis	1.5e-06	9.78e-06	CbGpPWpGaD
Olanzapine—HTR2B—Signaling Pathways—AKT1—atherosclerosis	1.49e-06	9.76e-06	CbGpPWpGaD
Olanzapine—CHRM3—Signaling Pathways—TGFB1—atherosclerosis	1.49e-06	9.75e-06	CbGpPWpGaD
Olanzapine—ADRA2A—Signaling Pathways—VEGFA—atherosclerosis	1.49e-06	9.75e-06	CbGpPWpGaD
Olanzapine—CYP3A4—Metabolism—PPARA—atherosclerosis	1.48e-06	9.7e-06	CbGpPWpGaD
Olanzapine—CHRM5—Signaling Pathways—AKT1—atherosclerosis	1.48e-06	9.66e-06	CbGpPWpGaD
Olanzapine—CHRM2—Signaling Pathways—TGFB1—atherosclerosis	1.48e-06	9.66e-06	CbGpPWpGaD
Olanzapine—ADRA2A—Signaling Pathways—STAT3—atherosclerosis	1.48e-06	9.65e-06	CbGpPWpGaD
Olanzapine—CYP2D6—Metabolism—PTGS2—atherosclerosis	1.48e-06	9.65e-06	CbGpPWpGaD
Olanzapine—ADRA1A—Signaling Pathways—TGFB1—atherosclerosis	1.47e-06	9.63e-06	CbGpPWpGaD
Olanzapine—CYP2C9—Metabolism—PTGS2—atherosclerosis	1.46e-06	9.56e-06	CbGpPWpGaD
Olanzapine—CYP3A4—Metabolism—AGT—atherosclerosis	1.44e-06	9.39e-06	CbGpPWpGaD
Olanzapine—CYP1A2—Metabolism—ALB—atherosclerosis	1.43e-06	9.34e-06	CbGpPWpGaD
Olanzapine—ADRA2A—Signaling Pathways—MAPK3—atherosclerosis	1.41e-06	9.22e-06	CbGpPWpGaD
Olanzapine—DRD1—Signaling Pathways—AKT1—atherosclerosis	1.41e-06	9.2e-06	CbGpPWpGaD
Olanzapine—CYP3A4—Metabolism—APOE—atherosclerosis	1.41e-06	9.2e-06	CbGpPWpGaD
Olanzapine—ADRA2C—Metabolism—AKT1—atherosclerosis	1.4e-06	9.16e-06	CbGpPWpGaD
Olanzapine—CYP3A4—Metabolism—CAV1—atherosclerosis	1.39e-06	9.12e-06	CbGpPWpGaD
Olanzapine—CYP3A4—Metabolism—APOA1—atherosclerosis	1.39e-06	9.1e-06	CbGpPWpGaD
Olanzapine—DRD3—Signaling Pathways—AKT1—atherosclerosis	1.39e-06	9.08e-06	CbGpPWpGaD
Olanzapine—ADRA2A—Signaling Pathways—TGFB1—atherosclerosis	1.37e-06	8.95e-06	CbGpPWpGaD
Olanzapine—CYP1A2—Metabolism—NOS3—atherosclerosis	1.37e-06	8.93e-06	CbGpPWpGaD
Olanzapine—ADRA2B—Signaling Pathways—IL6—atherosclerosis	1.36e-06	8.89e-06	CbGpPWpGaD
Olanzapine—HTR1A—Signaling Pathways—IL6—atherosclerosis	1.31e-06	8.58e-06	CbGpPWpGaD
Olanzapine—HTR2C—Signaling Pathways—IL6—atherosclerosis	1.31e-06	8.54e-06	CbGpPWpGaD
Olanzapine—CYP3A4—Metabolism—PIK3CG—atherosclerosis	1.27e-06	8.31e-06	CbGpPWpGaD
Olanzapine—ADRA2C—Signaling Pathways—IL6—atherosclerosis	1.27e-06	8.3e-06	CbGpPWpGaD
Olanzapine—ADRA2B—Signaling Pathways—AKT1—atherosclerosis	1.25e-06	8.2e-06	CbGpPWpGaD
Olanzapine—CYP1A2—Metabolism—PTGS2—atherosclerosis	1.25e-06	8.17e-06	CbGpPWpGaD
Olanzapine—ADRA1B—Signaling Pathways—IL6—atherosclerosis	1.25e-06	8.17e-06	CbGpPWpGaD
Olanzapine—CHRM3—Metabolism—AKT1—atherosclerosis	1.24e-06	8.11e-06	CbGpPWpGaD
Olanzapine—CYP3A4—Metabolism—PPARG—atherosclerosis	1.23e-06	8.02e-06	CbGpPWpGaD
Olanzapine—HTR1A—Signaling Pathways—AKT1—atherosclerosis	1.21e-06	7.91e-06	CbGpPWpGaD
Olanzapine—HTR2C—Signaling Pathways—AKT1—atherosclerosis	1.2e-06	7.87e-06	CbGpPWpGaD
Olanzapine—CYP3A4—Metabolism—INS—atherosclerosis	1.2e-06	7.86e-06	CbGpPWpGaD
Olanzapine—ADRA2C—Signaling Pathways—AKT1—atherosclerosis	1.17e-06	7.66e-06	CbGpPWpGaD
Olanzapine—ADRA1B—Signaling Pathways—AKT1—atherosclerosis	1.15e-06	7.54e-06	CbGpPWpGaD
Olanzapine—DRD2—Signaling Pathways—IL6—atherosclerosis	1.15e-06	7.53e-06	CbGpPWpGaD
Olanzapine—ADRA2A—Metabolism—AKT1—atherosclerosis	1.14e-06	7.44e-06	CbGpPWpGaD
Olanzapine—HTR2A—Signaling Pathways—IL6—atherosclerosis	1.13e-06	7.41e-06	CbGpPWpGaD
Olanzapine—HRH1—Signaling Pathways—IL6—atherosclerosis	1.13e-06	7.4e-06	CbGpPWpGaD
Olanzapine—CHRM1—Signaling Pathways—IL6—atherosclerosis	1.13e-06	7.37e-06	CbGpPWpGaD
Olanzapine—CHRM3—Signaling Pathways—IL6—atherosclerosis	1.12e-06	7.35e-06	CbGpPWpGaD
Olanzapine—CHRM2—Signaling Pathways—IL6—atherosclerosis	1.11e-06	7.28e-06	CbGpPWpGaD
Olanzapine—ADRA1A—Signaling Pathways—IL6—atherosclerosis	1.11e-06	7.26e-06	CbGpPWpGaD
Olanzapine—CYP3A4—Metabolism—ALB—atherosclerosis	1.1e-06	7.21e-06	CbGpPWpGaD
Olanzapine—DRD2—Signaling Pathways—AKT1—atherosclerosis	1.06e-06	6.95e-06	CbGpPWpGaD
Olanzapine—CYP3A4—Metabolism—NOS3—atherosclerosis	1.05e-06	6.9e-06	CbGpPWpGaD
Olanzapine—HTR2A—Signaling Pathways—AKT1—atherosclerosis	1.05e-06	6.84e-06	CbGpPWpGaD
Olanzapine—HRH1—Signaling Pathways—AKT1—atherosclerosis	1.04e-06	6.82e-06	CbGpPWpGaD
Olanzapine—CHRM1—Signaling Pathways—AKT1—atherosclerosis	1.04e-06	6.8e-06	CbGpPWpGaD
Olanzapine—CHRM3—Signaling Pathways—AKT1—atherosclerosis	1.04e-06	6.78e-06	CbGpPWpGaD
Olanzapine—ADRA2A—Signaling Pathways—IL6—atherosclerosis	1.03e-06	6.74e-06	CbGpPWpGaD
Olanzapine—CHRM2—Signaling Pathways—AKT1—atherosclerosis	1.03e-06	6.71e-06	CbGpPWpGaD
Olanzapine—ADRA1A—Signaling Pathways—AKT1—atherosclerosis	1.02e-06	6.7e-06	CbGpPWpGaD
Olanzapine—CYP3A4—Metabolism—PTGS2—atherosclerosis	9.65e-07	6.31e-06	CbGpPWpGaD
Olanzapine—ADRA2A—Signaling Pathways—AKT1—atherosclerosis	9.52e-07	6.22e-06	CbGpPWpGaD
Olanzapine—ALB—Metabolism—AKT1—atherosclerosis	8.98e-07	5.87e-06	CbGpPWpGaD
Olanzapine—CYP2C19—Metabolism—AKT1—atherosclerosis	8.06e-07	5.27e-06	CbGpPWpGaD
Olanzapine—ABCB1—Metabolism—AKT1—atherosclerosis	7.87e-07	5.14e-06	CbGpPWpGaD
Olanzapine—CYP2D6—Metabolism—AKT1—atherosclerosis	7.42e-07	4.85e-06	CbGpPWpGaD
Olanzapine—CYP2C9—Metabolism—AKT1—atherosclerosis	7.35e-07	4.81e-06	CbGpPWpGaD
Olanzapine—CYP1A2—Metabolism—AKT1—atherosclerosis	6.28e-07	4.11e-06	CbGpPWpGaD
Olanzapine—CYP3A4—Metabolism—AKT1—atherosclerosis	4.85e-07	3.17e-06	CbGpPWpGaD
